GlassScriptPhysician profile
Gabrielle Bramblett
NPI 1396261822
$1,175.11
in general payments reported to CMS, 2019-2025
21 companies · $36.93 in 2025
The $36.93 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $313 · 2022: $530 · 2023: $295 · 2025: $36.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $332.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $155.74 | 2022-2023 | Mounjaro, Trulicity |
| Novartis Pharmaceuticals Corporation | $121.25 | 2021-2023 | |
| Novo Nordisk INC | $119.94 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $108.49 | 2021-2023 | Xarelto |
| Abbvie INC. | $100.14 | 2021-2025 | |
| Amgen INC. | $83.61 | 2021-2023 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $78.19 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.57 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $51.24 | 2022-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $44.74 | 2021-2023 | |
| Abbott Laboratories | $43.90 | 2021-2023 | Octrode |
| Merck Sharp & Dohme LLC | $37.11 | 2021 | |
| Intuity Medical INC | $27.17 | 2022 | |
| Inari Medical, INC. | $25.75 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Lundbeck LLC | $21.84 | 2023 | Vyepti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $16.81 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.45 | 2023 | Xifaxan |
| Eisai INC. | $14.91 | 2021 | |
| Esperion Therapeutics, INC. | $14.81 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.82 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabrielle Bramblett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.